Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company save search
Pomerantz Law Firm Announces the Filing of a Class Action Against VinFast Auto Ltd. and Certain Officers - VFS
Published: 2024-04-12 (Crawled : 20:00) - prnewswire.com
FICO S | $1171.86 1.84% 22K
|
Technology Services
| Email alert
Add to watchlist
VFS | News | $2.47 1.65% 2.1M
|
| Email alert
Add to watchlist
BMY | $49.2 0.12% 2.9M
|
Health Technology
| Email alert
Add to watchlist
BSAQ | News | $10.2 2.45% 380
|
| Email alert
Add to watchlist
Eczema Therapeutics Market size is set to grow by USD 5.81 bn from 2024-2028,high prevalence of atopic dermatitis boost the market- Technavio
Published: 2024-04-08 (Crawled : 18:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: -3.43%
H: 6.21%
C: 6.21%
VTRS | News A | $11.365 1.02% 1.6M
|
Health Technology
|
| O: -0.25%
H: 1.1%
C: -0.17%
NVS | News | $97.63 2.64% 1.6M
|
Health Technology
|
| O: -0.05%
H: 0.43%
C: -0.27%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: -0.08%
H: 0.04%
C: -0.35%
BHC | $8.535 1.01% 480K
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: -7.27%
ABBV | News | $170.19 1.37% 1.6M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
AZN | News | $70.54 0.59% 1.7M
|
Health Technology
|
| O: 0.18%
H: 0.3%
C: 0.19%
eczema dermatitis set therapeutics market
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.745 2.04% 150K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Published: 2024-04-03 (Crawled : 08:00) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: -0.08%
H: 0.3%
C: -0.99%
reblozyl anemia approval treatment
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Published: 2024-04-02 (Crawled : 12:00) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.21%
H: 0.47%
C: -0.68%
report
Global Acute Lymphoblastic Leukemia Therapeutics Market Research 2024-2033: Developments Review, Regulatory Landscape, Competitive Benchmarking, Dynamic Landscape
Published: 2024-03-29 (Crawled : 18:00) - prnewswire.com
BMY | $49.2 0.12% 2.9M
|
Health Technology
| Email alert
Add to watchlist
GILD | $67.36 0.61% 1.2M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 600K
|
Health Technology
| Email alert
Add to watchlist
AMGN | News | $273.19 0.47% 360K
|
Health Technology
| Email alert
Add to watchlist
GMAB | News | $28.82 -0.52% 120K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.5 0.74% 450K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $95.11 490
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.63 2.64% 1.6M
|
Health Technology
| Email alert
Add to watchlist
GNMSF | News | $289.67 5.3K
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $170.19 1.37% 1.6M
|
Health Technology
| Email alert
Add to watchlist
research global leukemia therapeutics market
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
Published: 2024-03-28 (Crawled : 12:00) - globenewswire.com
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
LNTH | $64.7 2.58% 96K
|
Health Technology
|
| O: -0.25%
H: 3.58%
C: 3.2%
business year therapeutics financial results
Global Antibody Therapeutic Industry Research 2023-2024 & 2033: Exploring the Expanding Role in Managing Cancer, Autoimmune Disorders, and Infectious Diseases
Published: 2024-03-28 (Crawled : 15:30) - prnewswire.com
GLAXF | News | $20.305 630
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
NVSEF | News | $95.11 490
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | News | $97.63 2.64% 1.6M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
JNJ | News | $149.575 0.31% 2.5M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
GSK | News | $40.995 1.0% 590K
|
Health Technology
|
| O: 0.02%
H: 0.51%
C: -0.3%
LLY | News | $742.04 1.46% 540K
|
Health Technology
|
| O: 0.28%
H: 1.71%
C: -0.3%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
antibody research global
Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
first disease active update trial
Pharmaceutical Market In Canada size is set to grow by USD 8.73 bn from 2024-2028, Abbott Laboratories, AbbVie Inc. & Amgen Inc., and more to emerge as Some of the Key Vendors, Technavio
Published: 2024-03-27 (Crawled : 22:00) - prnewswire.com
GLAXF | News | $20.305 630
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: 0.0%
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -1.17%
H: 0.0%
C: -0.89%
AZNCF | News | $138.73 3.7K
|
Health Technology
|
| O: 0.89%
H: 0.78%
C: 0.78%
NVSEF | News | $95.11 490
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | News | $97.63 2.64% 1.6M
|
Health Technology
|
| O: 0.52%
H: 0.0%
C: 0.0%
GSK | News | $40.995 1.0% 590K
|
Health Technology
|
| O: 0.02%
H: 0.51%
C: -0.3%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.26%
H: 2.03%
C: 1.57%
ABBV | News | $170.19 1.37% 1.6M
|
Health Technology
|
| O: 0.36%
H: 0.72%
C: 0.61%
ABT | News | $107.565 0.46% 610K
|
Health Technology
|
| O: 1.04%
H: 0.0%
C: 0.0%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: 0.0%
AZN | News | $70.54 0.59% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.25%
C: -0.63%
AMGN | News | $273.19 0.47% 360K
|
Health Technology
|
| O: 0.54%
H: 0.0%
C: 0.0%
abbvie set canada key market
Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Published: 2024-03-26 (Crawled : 13:00) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.27%
H: 0.5%
C: 0.31%
health grant
Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
Published: 2024-03-25 (Crawled : 13:00) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.29%
H: 1.27%
C: 0.33%
cardiovascular cardiology
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
vmt01 melanoma nivolumab collaboration therapeutics agreement
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Published: 2024-03-18 (Crawled : 13:30) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
acquisition
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
Published: 2024-03-18 (Crawled : 15:30) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
acquisition therapeutics
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
TSVT | $4.745 2.04% 150K
|
|
| O: 2.27%
H: 8.4%
C: -0.99%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: -0.32%
H: 1.67%
C: 0.04%
fda therapy
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
Published: 2024-03-11 (Crawled : 23:00) - biospace.com/
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.2%
H: 1.22%
C: 0.85%
first report results
FDA Roundup: March 8, 2024
Published: 2024-03-08 (Crawled : 20:00) - prnewswire.com
BMY | $49.2 0.12% 2.9M
|
Health Technology
| Email alert
Add to watchlist
fda
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
Published: 2024-03-07 (Crawled : 12:00) - prnewswire.com
PFE | News A | $26.34 0.31% 7.7M
|
Health Technology
|
| O: 0.04%
H: 0.44%
C: -1.51%
NVS | News | $97.63 2.64% 1.6M
|
Health Technology
|
| O: -2.08%
H: 0.13%
C: -0.57%
BMY | $49.2 0.12% 2.9M
|
Health Technology
|
| O: 0.36%
H: 0.34%
C: -0.54%
XFOR | $1.335 -1.84% 1.2M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: -4.98%
EYPT | News | $18.34 8.2% 260K
|
Health Technology
|
| O: 2.56%
H: 1.37%
C: -4.13%
AQST | $4.345 -0.8% 800K
|
Health Technology
|
| O: 1.79%
H: 12.3%
C: 10.94%
ALKS | $24.58 2.12% 300K
|
Health Technology
|
| O: 1.11%
H: 0.96%
C: 0.65%
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.355 88.4% 34M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.75 79.52% 1.5M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.